Encompass Health raises 2025 adjusted EPS guidance to $5.22-$5.37 after Q3 profit rise
Encompass Health reported third-quarter 2025 net operating revenue of $1,477.5 million, up 9.4% from a year earlier, and adjusted earnings per share of $1.23, up from $1.03. The company raised its full-year 2025 guidance for adjusted EBITDA and adjusted EPS, and its revenue range was narrowed. Adjusted free cash flow fell 8.2% in the quarter, to $174.2 million.
Key points
- Q3 2025 diluted EPS from continuing operations was $1.24, up from $1.07; adjusted EPS was $1.23, up from $1.03.
- Q3 adjusted EBITDA was $300.1 million, up 11.4% from $269.3 million; adjusted free cash flow was $174.2 million, down from $189.7 million.
- Full-year 2025 adjusted EPS guidance rose to $5.22 to $5.37 from $5.12 to $5.34; adjusted EBITDA guidance rose to $1,235 million to $1,255 million from $1,220 million to $1,250 million.
- Full-year 2025 net operating revenue guidance was narrowed to $5,905 million to $5,955 million from $5,880 million to $5,980 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.